MEDX ... anybody following? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following?

MEDX 31.58

+1.4%

Nov 5 12:44 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (1763)	6/19/2007 3:47:58 PM
From: Icebrg	of 2240

Ok guys. How about a Danish language lesson? Biotekselskabet Genmab er fortsat i rampelyset efter uenighed blandt analytikere om effekten af antistoffet Humax-CD20 mod leddegigt og senest på fejloplysninger fra selskabets samarbejdspartner GlaxoSmithKline (GSK). Disse fejlagtige oplysninger fik tirsdag den amerikanske investeringsbank Bear Stearns til at nedjustere sin anbefaling af Genmab til "underperform" fra "peer perform". Men ifølge Genmab har GSK givet fejlagtige oplysninger om tidshorisonten for de kommende fase III data for Humax-CD20, idet GSK meddelte, at der først ville komme data fra fase III studierne i 2008. Genmab har hele tiden regnet med data for studierne i 2007 og bekræfter i dag, at tidsplanerne er uændrede. Aktien handles p.t. 1,7 pct. lavere i 375,50 kr. efter et fald på 4 pct. i går. Evidently, there is a downgrade by Bear Stearns from peer perform to underperform. The timetable for Humax-CD20 has been adjusted from 2007 to 2008. Etc. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next